The initial public offering (IPO) of Suraksha Diagnostic Limited, a healthcare sector company that offers pathology, radiology testing and medical consultancy services, will be open for subscription on November 29, 2024. The healthcare company has fixed a price band for the IPO between Rs 420 and Rs 441 with a face value of Rs 2 per share. It will be concluded in the next month i.e. December 3, 2024.

Suraksha Diagnostic Limited IPO | Key Details; BRLMs, Issue Size, Allocation & more

The issue size of the Suraksha Diagnostic Limited IPO is Rs 846.25 crore which comprises an offer for sale (OFS) of 1.91 crore shares, with no fresh issue component. Investors can bid for a minimum lot size of 34 shares and in multiples thereof. The allocation ratio for the issue is set at 50 per cent, 35 per cent, and 15 per cent for Qualified Institutional Buyers (QIBs), retail investors, and Non-Institutional Investors (NIIs), respectively.

Suraksha Diagnostic Limited IPO: BRLMS

The IPO is being managed by several leading wealth management companies like ICICI Securities, Nuvama Wealth Management, and SBI Capital Markets.

Suraksha Diagnostic Limited IPO: Registrar

The official registrar of Suraksha Diagnostic Limited IPO is KFin Technologies.

Suraksha Diagnostic Limited IPO: Important dates

As mentioned earlier the IPO will open for subscription on Friday, November 29, 2024, and close on Tuesday, December 3, 2024. The basis of allotment will be finalised on Wednesday, December 4, 2024. The stock will debut on the exchanges - BSE and NSE - on Friday, December 6, 2024.

Suraksha Diagnostic Limited IPO | Review

Analysts from two domestic brokerages outlined that the upper price band of the Suraksha Diagnostic Limited IPO is at premium pricing on the basis of earnings. Know here what they say:

Should you apply for Suraksha Diagnostic IPO? Here's what analysts recommend

According to SBI Securities' analysts, the upper price band of Rs 441 underscores the premium attributed to the company’s position as an integrated diagnostics provider, offering a one-stop solution for pathology, radiology, and medical consultation services. Importantly, the brokerage has not given any rating or any recommendation for the issue.

Meanwhile, even highlighting that the valuation metrics suggest premium pricing for the IPO, another domestic brokerage, Bajaj Broking has recommended to investors that apply for a long-term horizon.

Suraksha Diagnostic Limited IPO | Comparison with Peer Competitors

Here is a summary of the other healthcare diagnostic companies along with P/E, RoE, sales and more: